Search
Dalbavancin
go.drugbank.com/drugs/DB06219ApprovedInvestigationalDalbavancin is a second-generation lipoglycopeptide antibiotic that was designed to improve on the natural glycopeptides currently available, such as vancomycin and teicoplanin [A4072, A4073]. … Modifications from these older glycoprotein classes facilitated a similar mechanism of action for dalbavancin but with increased activity and once-weekly dosing [FDA Label, F2356, A4072, A4073].
Products: Dalbavancin Accord 500 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, Dalbavancin ratiopharm 500 mg Pulver für ein Konzentrat zur Herstellung einer InfusionslösungSaquinavir
go.drugbank.com/drugs/DB01232ApprovedInvestigationalIn 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a relatively benign adverse effect profile as compared … [A214382] While its efficacy was initially limited by exceptionally poor oral bioavailability (approximately 4%),[L3450] its current indications require the co-administration of ritonavir - a potent enzyme
Products: SAQUINAVIR 500 MG TABLETAS., SAQUINAVIR 500 MG TABLETA RECUBIERTADisulfiram
go.drugbank.com/drugs/DB00822ApprovedInvestigationalA carbamate derivative used as an alcohol deterrent. It is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol.
Products: ANTABUS 500 MG TABLET, 500 ADET, Antabus 400 mg lösliche TablettenIoxaglic acid
go.drugbank.com/drugs/DB09313ApprovedWithdrawnThis drug is an ionic tri-iodinated benzoate used as a low-osmolality contrast agent during diagnostic imaging procedures. … Ioxaglic acid has a low osmolarity and is associated with fewer side effects compared to older contrast agents [L1883].
Mixtures: Hexabrix 200, Hexabrix 200Categories: Compounds used in a research, industrial, or household settingPhenprocoumon
go.drugbank.com/drugs/DB00946ApprovedInvestigationalWithdrawnCoumarin derivative that acts as a long-acting oral anticoagulant.
Categories: Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic IndexProducts: MARCUPHEN ABZ 3 MG TAB, PHENPRO RATIOPHARM 3 MGDeucravacitinib
go.drugbank.com/drugs/DB16650ApprovedInvestigationalDeucravacitinib is a novel oral selective tyrosine kinase 2 (TYK2) inhibitor. … [A246938, A246943] This selectivity towards TYK2 may lead to an improved safety profile of deucravacitinib, as nonselective JAK inhibitors are associated with a range of adverse effects such as altered
Products: SOTYKTU 6 mg film coated tablets, SOTYKTU® 6MG TABLETAS RECUBIERTASFlunitrazepam
go.drugbank.com/drugs/DB01544ApprovedIllicitFlunitrazepam is a benzodiazepine with pharmacologic actions similar to those of diazepam that can cause anterograde amnesia. … Some reports indicate that it is used as a date rape drug and suggest that it may precipitate violent behavior. The United States Government has banned the importation of this drug.
Products: Rohypnol 1 mg - Filmtabletten, ROHYPNOL ROCHE TABLETAS 1 MGEncorafenib
go.drugbank.com/drugs/DB11718ApprovedInvestigationalEncorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. … [L12216] This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion.
Products: BRAFTOVI® 75 MG CÁPSULAS, BRAFTOVİ 75 MG SERT KAPSÜL, 42 ADETDelamanid
go.drugbank.com/drugs/DB11637ApprovedInvestigationalIt is used in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis (TB) in a combination regimen. … Emergence of multidrug-resistant and extensively drug-resistant tuberculosis creates clinical challenges for patients, as the disease is associated with a higher mortality rate and insufficient therapeutic
Products: Deltyba Film-Coated Tablets 50 mg, DELTYBA 50 MG FLİM TABLET, 40 ADETNeratinib
go.drugbank.com/drugs/DB11828ApprovedInvestigationalNeratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib i...
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: NERLYNX FILM-COATED TABLETS 40 MG, NERLYNX (neratinib) Film-Coated Tablets 40 mg